N/A
Completed N=93
Study Evaluating the Safety of Enbrel (Etanercept)
Arthritis, Psoriatic
Source: ClinicalTrials.gov NCT00683384 ↗
Enrolled (actual)
93
Serious AEs
1.1%
Results posted
Nov 2010
Primary outcomePrimary: Number of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection — 7 Participants
Summary
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection |
7 | — |
Eligibility Criteria
Inclusion Criteria
- All patients from the study center who received or will receive at least one dose of Enbrel according to the approved product indication.
Exclusion Criteria
- Previously discontinued Enbrel therapy due to significant safety concern.
Data sourced from ClinicalTrials.gov (NCT00683384). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.